The Kislinger Laboratory is located at the Princess Margaret Cancer Research Tower of the Princess Margaret Cancer Centre, the largest oncology treatment and research facility in Canada. The major goal of our lab is to apply proteomics technologies to cancer and cardiovascular research. Our research interests include technology development, using the latest generation of mass spectrometry instrumentation, basic cell biology and translational cancer research.
Qualitative determination of specific protein glycation products by matrix-assisted laser desorption/ionization mass spectrometry Peptide mapping.
J Agric Food Chem. 2002 Mar 27;50(7):2153-60
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses.
Circulation. 2002 Feb 19;105(7):816-22
Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.
Am J Pathol. 2001 Aug;159(2):513-25
Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice.
Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):905-10
Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
J Am Soc Nephrol. 2000 Sep;11(9):1656-66
Nature. 2000 May 18;405(6784):354-60
J Clin Invest. 2000 Apr;105(8):1117-24
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.
J Biol Chem. 1999 Oct 29;274(44):31740-9
Barbiturate induced benzophenanthridine alkaloid formation proceeds by gene transcript accumulation in the California poppy.
Biochem Biophys Res Commun. 1997 Dec 18;241(2):606-10
Senior Scientist, Princess Margaret Cancer Centre